ArticleChemical science2018
Synthetic biology approaches and combinatorial biosynthesis towards heterologous lipopeptide production.
Article in Chemical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Genome-Guided Metabolomic Profiling of Peptaibol-ProducingInternational journal of molecular sciences · 2025Article
- Synthetic Biology in Natural Product Biosynthesis.Chemical reviews · 2025Review
- Sources of Lipopeptides and Their Applications in Food and Human Health: A Review.Foods (Basel, Switzerland) · 2025Review
- Natural diversifying evolution of nonribosomal peptide synthetases in a defensive symbiont reveals nonmodular functional constraints.PNAS nexus · 2024Article
- Genetic manipulation and tools in myxobacteria for the exploitation of secondary metabolism.Engineering microbiology · 2023Review
- Knowledge-guided data mining on the standardized architecture of NRPS: Subtypes, novel motifs, and sequence entanglements.PLoS computational biology · 2023Article
- The modular pYT vector series employed for chromosomal gene integration and expression to produce carbazoles and glycolipids inFEMS microbes · 2023Article
- Type S Non-Ribosomal Peptide Synthetases for the Rapid Generation of Tailormade Peptide Libraries.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Recent Advances in Biocatalysis for Drug Synthesis.Biomedicines · 2022Review
- Underexplored bacteria as reservoirs of novel antimicrobial lipopeptides.Frontiers in chemistry · 2022Review
- Biotechnological production optimization of argyrins - a potent immunomodulatory natural product class.Microbial biotechnology · 2022Article
- Microbial production of small peptide: pathway engineering and synthetic biology.Microbial biotechnology · 2021Review
- Heterologous production of cyanobacterial compounds.Journal of industrial microbiology & biotechnology · 2021Review
- Review
- In vivo and in vitro reconstitution of unique key steps in cystobactamid antibiotic biosynthesis.Nature communications · 2021Article
- Simultaneous Multiplex Genome EngineeringFrontiers in microbiology · 2021Article
- Artificial Splitting of a Non-Ribosomal Peptide Synthetase by Inserting Natural Docking Domains.Angewandte Chemie (International ed. in English) · 2020Article
- Synthetic biology based construction of biological activity-related library of fungal decalin-containing diterpenoid pyrones.Nature communications · 2020Article
- Engineering enzymatic assembly lines to produce new antibiotics.Current opinion in microbiology · 2019Review
- Genetic platforms for heterologous expression of microbial natural products.Natural product reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic biology techniques coupled with heterologous secondary metabolite production offer opportunities for the discovery and optimisation of natural products. Here we developed a new assembly strategy based on type IIS endonucleases and elaborate synthetic DNA platforms, which could be used to seamlessly assemble and engineer biosynthetic gene clusters (BGCs). By applying this versatile tool, we designed and assembled more than thirty different artificial myxochromide BGCs, each around 30 kb in size, and established heterologous expression platforms using a derivative of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.